Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
5.44
-0.12 (-2.16%)
At close: Nov 4, 2024, 4:00 PM
5.48
+0.04 (0.74%)
After-hours: Nov 4, 2024, 5:30 PM EST
Company Description
Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors.
The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1.
This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
The company is headquartered in San Diego, California.
Skye Bioscience, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Punit Dhillon |
Contact Details
Address: 11250 El Camino Real, Suite 100 San Diego, California 92130 United States | |
| Phone | 858 410 0266 |
| Website | skyebioscience.com |
Stock Details
| Ticker Symbol | SKYE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001516551 |
| CUSIP Number | 83086J101 |
| ISIN Number | US83086J2006 |
| Employer ID | 45-0692882 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Punit S. Dhillon B.A. | Executive Chairman, President, Chief Executive Officer and Secretary |
| Kaitlyn Melanie Arsenault CPA | Chief Financial Officer |
| Dr. Christopher G. Twitty Ph.D. | Chief Scientific Officer |
| Tu Diep M.Sc. | Chief Development Officer |
| Dr. Puneet S. Arora FACE, M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 8-K | Current Report |
| Sep 23, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 13, 2024 | PRE 14A | Other preliminary proxy statements |
| Sep 4, 2024 | 8-K | Current Report |
| Aug 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Jul 3, 2024 | 8-K | Current Report |